

⑫

**EUROPEAN PATENT APPLICATION**

⑪ Application number: 87306663.3

⑪ Int. Cl.<sup>4</sup>: **C 12 Q 1/36**  
**C 07 K 5/00, C 07 K 7/00**

⑫ Date of filing: 28.07.87

⑬ Priority: 29.07.86 JP 179716/86  
30.09.86 JP 233848/86  
09.05.87 JP 113122/87

⑭ Date of publication of application:  
03.02.88 Bulletin 88/05

⑮ Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

⑰ Applicant: **SUNSTAR KABUSHIKI KAISHA**  
3-1, Asahi-machi  
Takatsuki-shi Osaka-fu (JP)

⑱ Inventor: **Tanaka, Toshiyuki**  
3-29-5 Nigawadanchi  
Takarazuka-shi Hyogo-ken (JP)

**Nakamura, Masakazu**  
No. 586-121 Miyagatanicho  
Takatsuki-shi Osaka-fu (JP)

**Suido, Hirohisa**  
No. 27-9 Hommachi  
Kawachinagano-shi Osaka-fu (JP)

⑲ Representative: **Ford, Michael Frederick et al**  
**MEWBURN ELLIS & CO. 2/3 Cursitor Street**  
London EC4A 1BQ (GB)

**⑳ Reagent for testing periodontal diseases.**

㉑ A reagent for testing periodontal diseases which diagnoses or prognosticates contraction or progress of said diseases by determining aminopeptidase-like enzymatic activity in a specimen, said reagent comprises as a substrate for the enzyme either or both compounds of the formula:

X-Z-Arg-Y [1]

wherein Arg is arginine residue; X is hydrogen or an amino blocking group; Y is a color developing group attached to the C-terminal of Arg; and Z is an amino acid or peptide residue composed of 1 to 4 amino acids or their blocked derivatives, the C-terminal of which is attached to the N-terminal of Arg, and X'-Z'-Pro-Y' [2]

wherein Pro is proline residue; X' is hydrogen or an amino blocking group; Y' is a color developing group attached to the C-terminal of Pro; and Z' is an amino acid or peptide residue composed of 0 to 4 amino acids or their blocked derivatives, the C-terminal of which is attached to the N-terminal of Pro.

## Descripti n

REAGENT FOR TESTING PERIODONTAL DISEASES

The present invention relates to a reagent for testing periodontal diseases. More particularly, it relates to a reagent which can detect certain pathogenic oral microorganisms for periodontal diseases specifically, readily and promptly to diagnose or prognosticate contraction or progress of such diseases.

Recently, bacteriological researches on periodontal diseases have advanced and, as a result, it has been found that many spirochetes are detected in sites with periodontal diseases and have good correlation with various clinical indices. Further, it has also been found that anaerobic gram negative bacteria are main pathogenic oral microorganisms for periodontal diseases. Among them, Black-pigmented Bacteroides such as B. gingivalis are particularly noted and many reports about their pathogenicities are present.

Then, attempts are made to detect these pathogenic bacteria in the oral cavity and to apply the results to clinical use so that periodontal diseases can be prevented or treated by prognosticating or diagnosing contraction or progress thereof.

However, there are some drawbacks in detection of these pathogenic oral bacteria by a bacteriological method. For example, detection requires highly skilled technique and special equipments such as use of a dark field microscope and handling of anaerobes, and involves complicated operations. Further, it takes long time and requires skill for cultivation and analysis of the result. Therefore, there are still many difficulties in application thereof to clinical practice.

From the immunological point of view, some attempts are made to detect the presence of the pathogenic microorganisms by determining antibody titer in blood which is humoral immunity to the pathogenic microorganisms, or determining lymphocyte blastformation which is cellular immunity. However, preparation of a specimen requires complicated operations and practical application is still difficult.

Under these circumstances, the present inventors have studied intensively to make detection of the pathogenic oral microorganisms for periodontal diseases applicable to clinical practice possible. As the result, the present inventors have found that some spirochetes in the oral cavity have very specific aminopeptidase-like enzymatic activities and Black-pigmented Bacteroides such as B. gingivalis, B. intermedius, B. corporis, B. melaninogenicus, B. Denticola and the like also have similar activities, which can be detected specifically, readily and promptly using particular substrates with precisely reflecting periodontal disease conditions.

It has been known heretofore in the prior art that oral spirochetes and B. gingivalis produce a trypsin-like enzyme and fibrinolysin [see, Journal of Clinical Microbiology, 97 - 102 (January, 1982); Microbios Letters, 25, 157 - 160 (1984); Journal of Dental Research, 65, 11, 1335-1340 (1986) and Journal of Periodontal Research, 21, 95-100 (1986)]. However, it is difficult to use these enzymes as indices because of problems in correlation with clinical conditions and specificity in detection.

The main object of the present invention is to provide a clinically applicable reagent for testing periodontal diseases which can detect certain pathogenic oral microorganisms for periodontal disease specifically, readily and promptly to diagnose or prognosticate contraction or progress of such diseases.

This object as well as other objects and advantages of the present invention will become apparent to those skilled in the art from the following description.

According to the present invention, there is provided a reagent for testing periodontal diseases which diagnoses or prognosticates contraction or progress of said diseases by determining aminopeptidase-like enzymatic activity in a specimen, said reagent comprises as a substrate for the enzyme either or both compounds of the formula:

X-Z-Arg-Y [1]

wherein Arg is arginine residue; X is hydrogen or an amino blocking group; Y is a color developing group attached to the C-terminal of Arg; and z is an amino acid or peptide residue composed of 1 to 4 amino acids or their blocked derivatives, the C-terminal of which is attached to the N-terminal of Arg, and

X'-Z'-Pro-Y' [2]

wherein Pro is proline residue; X' is hydrogen or an amino blocking group; Y' is a color developing group attached to the C-terminal of Pro; and Z' is an amino acid or peptide residue composed of 0 to 4 amino acids or their blocked derivatives, the C-terminal of which is attached to the N-terminal of Pro.

That is, in one aspect of the present invention, the reagent comprises as the substrate a compound of the formula [1].

In another aspect of the present invention, the reagent comprises as the substrate a compound of the formula [2].

In still another aspect of the present invention, the reagent comprises as the substrate both compounds of the formulas [1] and [2].

By using the reagent of the present invention, contraction or progress of periodontal diseases can be readily and promptly diagnosed or prognosticated by reacting a specimen such as saliva, dental plaque, gingival crevicular fluid or the like with the substrate of the formulas [1] and/or [2], preferably, under neutral conditions (pH 6.0 to 8.5) and determining the intensity of enzymatic hydrolysis activity by color development with a coloring reagent.

Thereby, according to the present invention, a desired diagnosis or prognostication of contraction or

progress of periodontal diseases can be made readily and promptly without requiring any special equipment or high technique, and adequate treatment and prevention of periodontal disease can be conducted.

The compounds of the formulas [1] and [2] used as the substrate in the present invention may be readily prepared by known peptide synthesis.

In the formulas [1] and [2], the amino blocking groups represented by X and X' may be any amino blocking group known in peptide synthesis such as formyl, acetyl, succinyl, t-butoxycarbonyl, benzoyl, carbobenzoxy, p-toluenesulfonyl and the like.

The color developing groups of Y and Y' may be any one used in determination of enzymatic activity by color development (including determination of absorption in ultraviolet, visible and infrared regions as well as determination of fluorescence). The typical examples include groups derived from  $\beta$ -naphthylamine, 4-methoxy-2-naphthylamine, p-nitroaniline, p-nitrophenol, 7-amino-4-methoxycoumarin, dimethyl-5-aminosophthalate, 7-amino-4-trifluoromethyl-coumarin, 3,5-dibrom-4-hydroxyaniline, p-N,N-disulfo-propylaminoaniline, 3-carboxy-4-hydroxyaniline, p-diethylaminoaniline and the like. Particularly preferred groups are those derived from  $\beta$ -naphthylamine, 4-methoxy-2-naphthylamine, p-nitroaniline, p-nitrophenol, 3,5-dibrom-4-hydroxyaniline, p-N,N-disulfo-propylaminoaniline, 3-carboxy-4-hydroxyaniline and p-diethylaminoaniline, which can show visually detectable color development with a suitable coloring reagent.

Z group may be any amino acid or peptide residue which composed of 1 to 4 amino acids or their blocked derivatives wherein C-terminal is attached to N-terminal of the arginine residue. Preferably, the C-terminal amino acid in the group Z is glycine, lysine, arginine, phenylalanine or their blocked derivatives. The blocked derivative includes a OH blocked serine, SH blocked cysteine,  $\beta$ - or  $\gamma$ -COOH blocked aspartic acid or glutamic acid, thereof is blocked by a suitable blocking group such as benzyl.

Z' group may be any amino acid or peptide residue which composed of 0 to 4 amino acids or their blocked derivatives (i.e., when the number of the amino acids is 0, the group Z' is not present in the formula [2]) wherein C-terminal is attached to N-terminal of the proline residue. Preferably, the C-terminal amino acid in the group Z' is glycine, lysine, phenylalanine or their blocked derivatives. The blocked derivative includes a OH blocked serine, SH blocked cysteine,  $\beta$ - or  $\gamma$ -COOH blocked aspartic acid or glutamic acid, thereof is blocked by a suitable blocking groups such as benzyl.

When the compound of the formula [1] is used together with the compound of the formula [2], X and X', Y and Y' as well as Z and Z' may be the same or different, respectively. However, preferably, Y and Y' are the same because color can be developed by using the same coloring reagent, simultaneously.

The configuration of each amino acid residue in the compounds of the formulas [1] and [2] is not specifically limited so long as it can be served as a substrate of an aminopeptidase-like enzyme.

The reagent of the present invention may be in any preparation form so long as the compounds of the formulas [1] and [2] can react as the substrate for the aminopeptidase-like enzyme from the specimen. Basically, it may be an aqueous solution of the compounds of the formulas [1] and/or [2], preferably, containing a buffer so that the pH thereof is adjusted to 6.0 to 8.5, when the measurement is carried out. There can be used any buffer which is usually used, for example, Tris-HCl buffer, phosphate buffer, borate buffer, veronal buffer, HEPES buffer or the like. The aqueous solution can be prepared according to a conventional method, for example, by dissolving the compounds of the formulas [1] and/or [2] and, if any, a buffer in distilled water. Further, optionally, other additives such as preservatives, antibiotics and the like may be added.

In the reagent of the present invention, preferably, the substrate can be used in a final concentration of 10 nM to 10 mM. When both compounds of the formulas [1] and [2] are used, the weight ratio of [1]/[2] is preferably 1 : 10 to 10 : 1. Preferably, the buffer can be used in a final concentration of 1 mM to 1 M. The above-mentioned aqueous solution can be so prepared that it contains either or both compounds of the formulas [1] and [2] and, if any, a buffer in these concentrations, and can be directly used for a test. Alternatively, it can be prepared into a concentrated solution which can be optionally diluted with distilled water to give a solution containing the substrate in a desired concentration, before use.

The reagent of the present invention may include solid preparations, for example, dry powder or granules obtained from the above-mentioned aqueous solution according to a known method; powder mixture obtained by mixing powder ingredients; granules obtained from such a powder mixture; or liquid preparations soaked in carriers such as filter paper, paper disc, sponge, polymers and the like.

The reagent of the present invention may be provided as a kit which comprises the reagent containing either or both compounds of the formulas [1] and [2] in combination with other reagents such as a buffer, a coloring reagent and the like.

The coloring reagent can be appropriately selected according to the groups Y and Y' in the compounds of the formulas [1] and [2]. For example, when the group is derived from  $\beta$ -naphthylamine, 4-methoxy-2-naphthylamine, p-nitroaniline or p-nitrophenol, there can be used a solution of Fast Garnet GBC or Fast Blue BB or a salt thereof such as a diazonium salt or a salt with zinc chloride in water, ethanol, an acetate buffer, 2-methoxyethanol or a mixture thereof in an concentration of 0.01 to 5% by weight, or a 0.5 to 5 M aqueous solution of sodium hydroxide, potassium hydroxide or acetic acid. These solutions or concentrated solutions thereof and further their solidified preparations can be used in combination with the reagent containing either or both compounds of the formulas [1] and [2] as the kit.

When a test for diagnosing or prognosticating contraction or progress of periodontal diseases is carried out using the reagent of the present invention, firstly, a specimen is collected. The specimen can be collected according to a known process. For example, gingival crevicular fluid and saliva can be collected with filter

paper, capillary, paper point and the like, and dental plaque can be collected with a swab, curette, scaler and the like.

Then, the reagent of the present invention, the final concentration of the substrate of which is adjusted to e.g. 10 nM to 10mM, is contacted with the specimen, for example, in a test tube, microtiter plate, vial, plastic cuvette or the like to subject the mixture to hydrolysis reaction, preferably, at pH of 6.0 to 8.5. This reaction is usually conducted at 15 to 45°C, preferably, 25 to 45°C. The reaction time varies depending on a particular specimen and reaction temperature. Preferably, the reaction is carried out at 37°C for 15 minutes to 72 hours.

After completion of the reaction, a coloring reagent is added and then the presence of color development or its intensity is evaluated with the naked eye, or with a spectrophotometer or a fluorophotometer to determine the presence or intensity of aminopeptidase-like enzymatic activity in the specimen. Thus, contraction or progress of periodontal disease can be diagnosed or prognosticated.

The following Experiments and Examples further illustrate the present invention in detail but are not to be construed to limit the scope thereof.

## Experiment 1

Aminopeptidase-like enzymatic activity of various kinds of oral anaerobes

Oral anaerobes, i.e., four strains of *Treponema denticola*, five strains of *B. gingivalis*, four strains of *Actinobacillus actinomycetemcomitans*, four strains of *Capnocytophaga* sp. and three strains of *Fusobacterium nucleatum* were tested for hydrolysis activity to the substrate of aminopeptidase-like enzyme as follows.

The strains of *Treponema* were anaerobically cultivated using TYGUS media at 37°C for 7 days, while other bacterial strains were cultivated using brain heart infusion broth at 37°C for 48 to 72 hours. Each culture was diluted to obtain a bacterial cell suspension, the absorption at 660 nm of which was 1.0.

Substrate compounds for aminopeptidase-like enzyme having various color developing groups derived from  $\beta$ -naphthylamine were dissolved in 0.1 M Tris-HCl buffer (pH 7.0) at the concentration of 0.2 mM to obtain substrate solutions.

To the substrate solution (1.5 ml) was added the above cell suspension (0.3 ml) and reacted at 37°C for 60 minutes. After completion of the reaction, a coloring reagent [prepared by dissolving diazonium salt of Garnet GBC in 1 M acetate buffer (containing 10 % Tween 20, pH: 4.2) at the concentration of 0.5 mg/ml] was added and, after 15 minutes, the absorption at 525 nm was determined with a spectrophotometer.

On the basis of the average amount of released  $\beta$ -naphthylamine in each strain, the hydrolytic activity was expressed as follows:

- : release amount < 5 nmol/ml

$\pm$  :  $5 \leq$  release amount < 10 nmol/ml

+ :  $10 \leq$  release amount < 20 nmol/ml

++ :  $20 \leq$  release amount < 40 nmol/ml

+++ : release amount  $\geq$  40 nmol/ml

The results are shown in Table 1. Abbreviations used in Table 1 mean the following substrate compounds.

A: alanine- $\beta$ -naphthylamide

G: glycine- $\beta$ -naphthylamide

R: arginine- $\beta$ -naphthylamide

K: lysine- $\beta$ -naphthylamide

GR: glycyl-arginine- $\beta$ -naphthylamide

RR: arginyl-arginine- $\beta$ -naphthylamide

RG: arginyl-glycine- $\beta$ -naphthylamide

KR: lysyl-arginine- $\beta$ -naphthylamide

FR: phenylalanyl-arginine- $\beta$ -naphthylamide

GK: glycyl-lysine- $\beta$ -naphthylamide

GF: glycyl-phenylalanine- $\beta$ -naphthylamide

PFR: prolyl-phenylalanyl-arginine- $\beta$ -naphthylamide

BzGR: N-benzoyl-glycyl-arginine- $\beta$ -naphthylamide

CxRR: N-carbobenzoxymethyl-arginyl-arginine- $\beta$ -naphthylamide

CxFR: N-carbobenzoxymethyl-phenylalanyl-arginine- $\beta$ -naphthylamide

CxKR: N-carbobenzoxymethyl-lysyl-arginine- $\beta$ -naphthylamide

CxVGR: N-carbobenzoxymethyl-valyl-glycyl-arginine- $\beta$ -naphthylamide

BzVGR: N-benzoyl-valyl-glycyl-arginine- $\beta$ -naphthylamide

BcVLGR: N-t-butoxycarbonyl-valyl-leucyl-glycyl-arginine- $\beta$ -naphthylamide

ScGPLGR: N-succinyl-glycyl-prolyl-leucyl-glycyl-arginine- $\beta$ -naphthylamide

Table 1

<u>Strain</u>	<u>Substrate</u>									
	A	G	R	K	GR	RR	RG	KR	FR	GK
<u>Treponema denticola</u>	-	-	-	-	+	+++	-	+	+	-
<u>Bacteroides gingivalis</u>	-	-	-	-	++	+	++	++	+	+
<u>Actinobacillus actinomy-</u> <u>mycetemcomitans</u>	-	-	+	-	-	-	-	-	-	-
<u>Capnocytophaga sp.</u>	+++	+	+++	+++	±	+	+	+	±	+
<u>Fusobacterium nucleatum</u>	-	-	-	-	-	-	-	-	-	-

Table 1 (continued)

Strain	Substrate									
	GF	PFR	BzGR	CxRR	CxFR	CxKR	CxVGR	BzVGR	BcVLGR	ScGPLGR
<u>Treponema denticola</u>	-	+++	++	++	+++	++	+++	+++	++	+
<u>Bacteroides gingivalis</u>	++	+++	+++	+++	+++	++	+++	+++	++	++
<u>Actinobacillus actinomycescomitans</u>	-	-	-	-	-	-	-	-	-	-
<u>Capnocytophaga sp.</u>	+	-	-	-	-	-	-	-	-	-
<u>Fusobacterium nucleatum</u>	-	-	-	-	-	-	-	-	-	-

As is shown in Table 1, among the oral anaerobes, pathogenic spirochete for periodontal diseases (Treponema denticola) and B. gingivalis show specific aminopeptidase-like enzymatic activity, and specifically

hydrolyze the compound of the formula [1] among various substrate compounds.

## Experiment 2

According to the same manner as described in Experiment 1, aminopeptidase-like enzymatic activity was tested by using four strains of *Treponema denticola*, five strains of *B. gingivalls*, three strains of *B. Intermedius*, two strains of *B. melaninogenicus*, two strains of *Actinomyces Israelii*, four strains of *Actinobacillus actinomycetemcomitans* and three strains of *Fusobacterium nucleatum*. The results are shown in Table 2. Abbreviations used in Table 2 mean the following substrate compounds.

A: alanine- $\beta$ -naphthylamide  
 G: glycine- $\beta$ -naphthylamide  
 R: arginine- $\beta$ -naphthylamide  
 K: lysine- $\beta$ -naphthylamide  
 P: proline- $\beta$ -naphthylamide  
 VA: valyl-alanine- $\beta$ -naphthylamide  
 LG: leucyl-glycine- $\beta$ -naphthylamide  
 SY: seryl-tyrosine- $\beta$ -naphthylamide  
 FP: phenylalanyl-proline- $\beta$ -naphthylamide  
 KP: lysyl-proline- $\beta$ -naphthylamide  
 GP: glycyl-proline- $\beta$ -naphthylamide  
 CxKP: N-carbobenzoxy-lysyl-proline- $\beta$ -naphthylamide  
 BzGP: N-benzoyl-glycyl-proline- $\beta$ -naphthylamide  
 BzGFP: N-benzoyl-glycyl-phenylalanyl-proline- $\beta$ -naphthylamide  
 CxVKP: N-carbobenzoxy-valyl-lysyl-proline- $\beta$ -naphthylamide  
 CxPAGP: N-carbobenzoxy-prolyl-alanyl-glycyl-proline- $\beta$ -naphthylamide  
 BzRGFP: N-benzoyl-arginyl-glycyl-phenylalanyl-proline- $\beta$ -naphthylamide  
 ScGPLGP: N-succinyl-glycyl-prolyl-leucyl-glycyl-proline- $\beta$ -naphthylamide

Table 2

Strain	Substrate									
	A	G	R	K	P	VA	LG	SY	FP	KP
<u>Treponema denticola</u>	-	-	-	-	+	-	-	-	++	++
<u>B. gingivalis</u>	-	-	-	-	-	++	+	++	++	+++
<u>B. intermedius</u>	-	-	-	-	-	-	-	-	+	++
<u>B. corporis</u>	-	-	-	-	-	±	++	±	+	++
<u>B. melaninogenicus</u>	-	-	-	-	-	±	+++	±	+	++
<u>B. denticola</u>	-	-	-	-	-	±	++	±	+	++
<u>Fusobacterium nucleatum</u>	-	-	-	-	-	-	-	-	-	-
<u>Actinobacillus actinomycescomitans</u>	-	-	-	-	-	-	-	-	-	-
<u>Actinomyces israeli</u>	-	-	-	-	-	-	-	-	-	-



Table 2 (continued)

Strain	Substrate							
	GP	CxKP	BzCP	BzGFP	CxVKP	CxPAGP	BzRGFP	ScGPLGP
<u>Treponema denticola</u>	++	+	++	+++	++	+++	++	+
<u>B. gingivalis</u>	+++	++	++	++	++	+	++	±
<u>B. intermedius</u>	+	++	+++	+++	++	+++	+++	+
<u>B. corporis</u>	++	++	++	++	++	++	++	±
<u>B. melaninogenicus</u>	++	++	++	++	++	+++	+++	±
<u>B. denticola</u>	+	++	++	++	++	+++	+++	±
<u>Fusobacterium nucleatum</u>	-	-	-	-	-	-	-	-
<u>Actinobacillus actinomycescomitans</u>	-	-	-	-	-	-	-	-
<u>Actinomyces israelii</u>	-	-	-	-	-	-	-	-

Likewise, the results of Table 2 shows that, among the oral anaerobes, pathogenic spirochete for periodontal diseases (Treponema denticola) and Black-pigmented Bacteriodes show specific aminopepti-

dase-like enzymatic activity, and specifically hydrolyze the compound of the formula [2] among various substrate compounds.

### Experiment 3

5 According to the same manner as described in Experiment 1, aminopeptidase-like activity was tested by using four strains of Treponema denticola, five strains of B. gingivalis, four strains of Actinobacillus actinomycetemcomitans, two strains of Actinomyces israeli and three strains of Fusobacterium nucleatum. The results are shown in Table 3. Abbreviation in Table 3 are the same as those in Tables 1 and 2. Hydrolytic activity "+ + +" means " $40 \leq$  release amount < 80 nmol/ml" and "+ + + +" means "release amount  $\geq$  80 nmol/ml".

15

20

25

30

35

40

45

50

55

60

65

Table 3

<u>Strain</u>	<u>Substrate</u>					
	GR	BzGR	CxVGR	GP	CxKP	BzRGFP
<u>Treponema denticola</u>	+	++	+++	++	+	++
<u>B. gingivalis</u>	++	+++	+++	+++	++	++
<u>Actinobacillus actinomy-</u> <u>mycetemcomitans</u>	-	-	-	-	-	-
<u>Actinomyces israelii</u>	-	-	-	-	-	-
<u>Fusobacterium nucleatum</u>	-	-	-	-	-	-

Table 3 (continued)

Strain	Substrate		
	BzGR + CxKP	CxVGR + BzRGFP	BzGP + BzRGFP
<u>Treponema denticola</u>	+++	++++	+++
<u>B. gingivalis</u>	++++	++++	++++
<u>Actinobacillus actinomy-</u> <u>mycetemcomitans</u>	-	-	-
<u>Actinomyces israelii</u>	-	-	-
<u>Fusobacterium nucleatum</u>	-	-	-

As shown in Table 3, when the compound of the formula [1] is used together with the compound of the formula [2], the enzymatic activity is increased twice or three times as much as that obtained by using either

compound of the formula [1] or [2] alone.

#### Experiment 4

##### Correlation for clinical state (1)

Specimens of gingival crevicular fluid were collected with paper points from five subjects who were considered to be healthy from their clinical state, six subjects with gingivitis and six subjects with periodontitis. Each specimen was dispersed in Ringer's solution (1.5 ml), and the relative amount of spirochete to total bacteria:

EMI PA=23 FR=1 HE=15 WI=145 TI=MAT

was determined with a phase contrast microscope. Further, the Ringer's solution (0.3 ml) was tested for hydrolytic activity using the substrate solution prepared in the same manner as described in Experiment 1. As substrates, there were used compounds of the formula [1], i.e., N-benzoyl-valyl-glycyl-arginine- $\beta$ -naphthylamide (BzVGR) and N-carbobenzoxy-valyl-glycyl-arginine- $\beta$ -naphthylamide (CxVGR) were used.

The results are shown in Table 4. In table 4, hydrolytic activity was visually evaluated and expressed as follows:

- : orange
- +: dark orange
- ++: brown
- +++ : dark brown

Table 4

	<u>Subject</u>	Amount of <u>Spirochete(%)</u>	<u>Substrate</u>	
			BzVGR	CxVGR
5				
10	Healthy			
	1	0.1	-	-
15	2	2.5	+	+
	3	1.1	-	-
20	4	0.6	-	-
	5	1.3	-	-
25	Gingivitis			
	1	7.3	+	+
	2	16.7	+	+
30	3	20.5	++	++
	4	6.8	-	-
35	5	7.3	-	-
	6	14.4	+	+
40	Periodontitis			
	1	45.2	+++	+++
45	2	30.3	+++	+++
	3	34.6	+++	+++
	4	21.2	+++	+++
50	5	40.3	+++	+++
	6	35.1	+++	+++
55				
60				

As shown in Table 4, hydrolytic activity has correlation for the amount of spirochete and the clinical state.  
 There is no difference in reactivity between the two substrates.

**Experiment 5**

According to the same manner as described in Experiment 4, hydrolytic activity was tested by using the compounds of the formula [2], i.e., lysyl-proline- $\beta$ -naphthylamide (KP) and N-carbobenzoxy-prolyl-alanyl-glycyl-proline- $\beta$ -naphthylamide (CxPAGP) as the substrates. The results are shown in Table 5.

5

10

15

20

25

30

35

40

45

50

55

60

65

Table 5

Table 5				
	<u>Subject</u>	Amount of <u>Spirochete(%)</u>	<u>Substrate</u>	
			KP	CxPAGP
5				
10	Healthy			
	1	0.1	-	-
15	2	2.5	+	+
	3	1.1	-	-
20	4	0.6	-	-
	5	1.3	-	-
25	Gingivitis			
	1	7.3	+	+
30	2	16.7	+	+
	3	20.5	++	++
35	4	6.8	-	-
	5	7.3	-	-
40	6	14.4	+	+
	Periodontitis			
	1	45.2	+++	+++
45	2	30.3	+++	+++
	3	34.6	+++	+++
50	4	21.2	+++	+++
	5	40.3	+++	+++
55	6	35.1	+++	+++

65 Likewise, hydrolytic activity has correlation for the clinical state and there is no difference in reactivity between both substrates.



Experiment 6

According to the same manner as described in Experiment 4, hydrolytic activity was tested by using the compounds of the formulas [1] and [2], i.e., glycyl-proline- $\beta$ -naphthylamide (GP), N-benzoyl-arginyl-glycyl-phenylalanyl-proline- $\beta$ -naphthylamide (BzRGFP), N-carbobenzoxy-valyl-glycyl-arginine- $\beta$ -naphthylamide (CxVGR) and N-benzoyl-glycyl-arginine- $\beta$ -naphthylamide (BzGR) alone or in combination. Hydrolytic activity was determined by measuring absorption at 525 nm ( $OD_{525}$ ) and expressed as follows.

-:  $OD_{525} < 0.1$

+:  $0.1 \leq OD_{525} < 0.2$

++:  $0.2 \leq OD_{525} < 0.4$

+++:  $0.4 \leq OD_{525} < 0.8$

++++:  $0.8 \leq OD_{525}$

The results are shown in Table 6.

Table 6

<u>Subject</u>	Amount of	<u>Substrate</u>	
	<u>Spirochete(%)</u>	CxVGR	BzGR
Healthy			
1	0.1	-	-
2	2.5	+	±
3	1.1	-	-
4	0.6	-	-
5	1.3	-	-
Gingivitis			
1	7.3	+	+
2	16.7	+	+
3	20.5	++	++
4	6.8	-	-
5	7.3	-	-
6	14.4	+	±
Periodontitis			
1	45.2	+++	++
2	30.3	+++	++
3	34.6	+++	++
4	21.2	+++	++
5	40.3	+++	++
6	35.1	+++	++

Table 6 (continued)

Subject	Substrate				
	GP	BzRGFP	CxVGR + GP	BzGR + BzRGFP	
Healthy					10
1	-	-	-	-	15
2	±	+	+	+	
3	-	-	-	-	20
4	-	-	-	-	
5	-	-	-	-	25
Gingivitis					
1	+	+	+	+	30
2	+	+	++	++	
3	++	++	++	++	35
4	-	-	-	-	
5	-	-	-	-	40
6	+	+	+	++	
Periodontitis					
1	+++	+++	++++	++++	45
2	+++	+++	++++	++++	
3	+++	+++	++++	++++	50
4	++	+++	++++	++++	
5	+++	+++	++++	++++	55
6	+++	+++	++++	++++	

As shown in Table 6, when the compound of the formula [1] is used together with the compound of the formula [2], hydrolytic activity of the specimen is considerably increased.

Experiment 7

## Correlation with clinical state (2)

5 A saliva mixture was collected from a group consisting of ten healthy subjects and centrifuged to obtain a supernatant. Likewise, centrifuged supernatants were obtained from a group of ten subjects with adult periodontitis and a group of four localized juvenile periodontitis. The supernatant was used as a specimen and its hydrolytic activity was determined according to the same manner as described in Experiment 4 except that the reaction was carried out at 37° C for 4 hours. As the substrates, there were used N-carbobenzoxy-valyl-glycyl-arginine-p-nitroanilide (CxVGR-pNA), N-carbobenzoxy-valyl-glycyl-arginine-4-methoxy-2-naphthylamide (CxVGR-4NA) and N-carbobenzoxy-valyl-glycyl-arginine-β-naphthylamide (CxVGR-βNA). Color was developed by using 1N sodium hydroxide for CxVGR-pNA and Fast Blue BB for CxVGR-4NA and CxVGR-βNA. The results are shown in Table 7.

Table 7

<u>Substrate</u>	<u>Group</u>		
	Healthy subjects	Adult Periodontitis subjects	Localized juvenile periodontitis subjects
CxVGR-pNA	17.0 ± 11.4	34.0 ± 9.7*	32.5 ± 9.6**
CxVGR-4NA	18.0 ± 10.8	34.6 ± 8.9*	32.3 ± 8.9**
CxVGR-βNA	16.1 ± 10.3	35.6 ± 9.8*	33.4 ± 10.0**

\*:  $p < 0.01$

\*\* :  $p < 0.05$

As shown in Table 7, both subjects with adult periodontitis and localized juvenile periodontitis have more than twice as high values (activities) as that of healthy subjects and the difference is statistically significant.

Experiment 8

According to the same manner as described in Experiment 7, hydrolytic activity was tested by using lysyl-proline-p-nitroanilide (KP-pNA), lysyl-proline-4-methoxy-2-naphthylamide (KP-4NA) and lysyl-proline-β-naphthylamide (KP-βNA) as the substrates. Color was developed by using 1N sodium hydroxide for KP-pNA and Fast Blue BB for KP-4NA and KP-βNA. The results are shown in Table 8.

Table 8

<u>Substrate</u>	(nmol/ml)			
	Healthy subjects	Adult Periodontitis subjects	Localized juvenile periodontitis subjects	
KP-pNA	15.0 ± 9.4	34.3 ± 9.8*	31.5 ± 9.7**	15
KP-4NA	16.0 ± 10.8	35.5 ± 10.1*	32.3 ± 8.9**	
KP-βNA	16.1 ± 10.3	36.2 ± 9.9*	33.4 ± 10.0**	20
*: p < 0.01				25
**: p < 0.05				

Likewise, both subjects with adult periodontitis and localized juvenile periodontitis have more than twice as high values (activities) as that of healthy subjects and the difference is statistically significant.

#### Experiment 9

According to the same manner as described in Experiment 7, hydrolytic activity was tested by using N-carbobenzoxy-valyl-glycyl-arginine-β-naphthylamide (CxVGR-βNA), N-benzoyl-arginyl-glycyl-phenylalanyl-proline-β-naphthylamide (BzRGFP-βNA), N-carbobenzoxy-valyl-glycyl-arginine-p-nitroanilide (CxVGR-pNA) and N-benzoyl-arginyl-glycyl-phenylalanyl-proline-p-nitroanilide (BzRGFP-pNA) alone or in combination as the substrates. The results are shown in Table 9.

Table 9

Substrate	(nmol/ml)		
	Healthy subjects	Adult Periodontitis subjects	Localized juvenile periodontitis subjects
CxVGR- $\beta$ NA	15.0 $\pm$ 8.8	34.8 $\pm$ 10.2*	31.5 $\pm$ 9.8**
BzRGFP- $\beta$ NA	13.2 $\pm$ 5.4	27.8 $\pm$ 7.4*	22.6 $\pm$ 5.3**
CxVGR- $\beta$ NA + BzRGFP- $\beta$ NA	18.4 $\pm$ 8.3	50.2 $\pm$ 15.3*	42.2 $\pm$ 13.4**
CxVGR-pNA	14.0 $\pm$ 7.9	33.5 $\pm$ 11.5*	28.8 $\pm$ 9.1**
BzRGFP-pNA	13.3 $\pm$ 4.9	25.6 $\pm$ 8.4*	21.8 $\pm$ 7.8**
CxVGR-pNA + BzRGFP-pNA	18.6 $\pm$ 8.1	49.8 $\pm$ 14.4*	44.5 $\pm$ 12.8**
*: p < 0.01			
**: p < 0.05			

Likewise, both subjects with adult periodontitis and localized juvenile periodontitis have higher values (activities) than that of healthy subjects and the difference is statistically significant.

Accordingly, objective diagnosis and prognostication of periodontal diseases can be carried out by using the reagent of the present invention to determine hydrolytic activity of oral pathogenic microorganisms for periodontal diseases.

#### Example 1

As a substrate solution, a solution of N-carbobenzoxy-valyl-glycyl-arginine-4-methoxy-2-naphthylamide in distilled water (2 mM) was prepared.

As a buffer, 0.1 M Tris-HCl buffer (pH 7.0) was prepared.

As a coloring reagent, diazonium salt of Garnet GBC was dissolved in 1 M acetate buffer (pH 4.0) containing 10% of Tween 20 at a concentration of 0.5 mg/ml.

These reagents were combined and used as a kit for testing periodontal diseases.

This kit can be used for diagnosis or prognostication of periodontal diseases as follows.

A paper point is inserted into the gingival crevice of a subject for 30 seconds to collect a specimen. The substrate solution (0.1 ml) and the buffer (0.9 ml) are mixed and the specimen is added to the mixture. The mixture is allowed to react at 37°C for 24 hours. After completion of the reaction, the coloring reagent (0.3 ml) is added. After 15 minutes at room temperature, a color tone is observed by the naked eye. The intensity of brown color is evaluated by comparing with a blank control. Heavy brown color shows that the subject has periodontal diseases.

#### Example 2

A substrate reagent was prepared by soaking a paper disc (diameter 0.6 cm) with N-benzoyl-valyl-glycyl-arginine-4-methoxy-2-naphthylamide (500 nmol).

0.1 M Phosphate buffer (pH 7.2) was used as a buffer.

These reagents and the coloring reagent prepared in the same manner as described in Example 1 were combined and used as a kit for testing periodontal diseases.

This kit can be used for diagnosis or prognostication of periodontal diseases as follows:

The buffer solution (400  $\mu$ l) was placed in a vial to which are added saliva (100  $\mu$ l) collected from a subject and the paper disc of the substrate reagent. The mixture is reacted at 37°C for 4 hours. After completion of the reaction, the coloring reagent is added and color development is evaluated by the naked eye according to the

same manner as described in Example 1.

#### Example 3

N-carbobenzoxy-arginyl-arginine-4-methoxy-2-naphthylamide (500 nmol) was lyophilized in an ampoule (inner diameter 5 mm; length 3 cm) to prepare a substrate reagent.

0.05 M Tris-HCl buffer (pH 7.5) was prepared and used as a buffer.

Diazonium salt of Fast Blue B was dissolved in 1 M acetate buffer (pH 4.2) containing 10% of Tween at the concentration of 1 mg/ml and used as a coloring reagent.

These reagents were combined and used as the kit for testing periodontal diseases.

This kit can be used for diagnosis or prognostication of periodontal diseases as follows.

A paper strip is inserted into the gingival crevice of a subject for 30 seconds to collect a specimen. The buffer (1 ml) is poured in an ampoule containing the substrate to dissolve it. The specimen is added to the solution and reacted at 37°C for 24 hours. After completion of the reaction, the coloring reagent (0.4 ml) is added and color development is evaluated according to the same manner as described in Example 1.

#### Example 4

N-t-Butoxycarbonyl-valyl-leucyl-glycyl-arginine-β-naphthylamide was dissolved in 0.05 M phosphate buffer (pH 7.2) in the concentration of 200 nmol/ml and a circular filter paper (diameter 1 cm) was soaked with the solution (100 μl), dried and placed at the bottom of a cuvette (inner diameter 1 cm) to prepare a substrate reagent.

This reagent was combined with the coloring reagent prepared in the same manner as described in Example 3 and used as a kit for testing periodontal diseases.

This kit can be used for diagnosis or prognostication of periodontal diseases as follows.

Saliva (100 μl) collected from a subject is added to the cuvette and reacted at 37°C for 4 hours. After completion of the reaction, the coloring reagent (40 μl) is added and color development is evaluated according to the same manner as described in Example 1.

#### Example 5

According to the same manner as described in Example 1, a substrate solution was prepared except that lysyl-proline-4-methoxy-2-naphthylamide was used instead of N-carbobenzoxy-valyl-glycyl-arginine-4-methoxy-2-naphthylamide.

The substrate solution can be used as a kit for testing periodontal diseases according to the same manner as described in Example 1.

#### Example 6

According to the same manner as described in Example 2, a substrate reagent was prepared except that lysyl-proline-4-methoxy-2-naphthylamide was used instead of N-benzoyl-valyl-glycyl-arginine-4-methoxy-2-naphthylamide.

This substrate reagent can be used as a kit for testing periodontal diseases according to the same manner as described in Example 2.

#### Example 7

According to the same manner as described in Example 3, a substrate reagent was prepared except that N-carbobenzoxy-prolyl-alanyl-glycyl-proline-β-naphthylamide was used instead of N-carbobenzoxy-arginyl-arginine-4-methoxy-2-naphthylamide.

This substrate reagent can be used as a kit for testing periodontal diseases according to the same manner as described in Example 3.

#### Example 8

According to the same manner as described in Example 4, a substrate reagent was prepared except that N-benzoyl-arginyl-glycyl-phenylalanyl-proline-β-naphthylamide instead of N-t-butoxycarbonyl-valyl-leucyl-glycyl-arginine-β-naphthylamide.

This substrate reagent can be used as a kit for testing periodontal diseases according to the same manner as described in Example 4.

#### Example 9

2 mM solution of N-carbobenzoxy-valyl-glycyl-arginine-4-methoxy-2-naphthylamide in distilled water was mixed with the same amount of 2 mM solution of N-benzoyl-lysyl-proline-4-methoxy-2-naphthylamide in distilled water to prepare a substrate solution.

This substrate solution can be used as a kit for testing periodontal diseases according to the same manner as described in Example 1.

#### Example 10

A substrate reagent was prepared by soaking a paper disc (diameter 0.6 cm) with N-benzoyl-valyl-glycyl-arginine-4-methoxy-2-naphthylamide (500 nmol) and N-benzoyl-prolyl-alanyl-glycyl-proline-4-methoxy-2-naph-

thylamide (250 nmol).

This substrate reagent can be used as a kit for testing periodontal diseases according to the same manner as described in Example 2.

#### 5 Example 11

N-carbobenzoxy-arginyl-arginine-4-methoxy-2-naphthylamid (500 nmol) and N-benzoyl-arginyl-glycyl-phenylalanyl-proline- $\beta$ -naphthylamide (500 nmol) were lyophilized in an ampoule (inner diameter 5 mm; length 3 cm) to prepare a substrate reagent.

10 This substrate reagent can be used as a kit for testing periodontal diseases according to the same manner as described in Example 3.

#### Example 12

15 N-t-butoxycarbonyl-valyl-leucyl-glycyl-arginine- $\beta$ -naphthylamide was dissolved in 0.05 M phosphate buffer (pH 7.2) in a concentration of 400 nmol/ml. Likewise, lysyl-proline- $\beta$ -naphthylamide was dissolved in 0.05 M phosphate buffer (pH 7.2) in a concentration of 400 nmol/ml. The same amounts of both solutions were mixed and a circular filter paper (diameter 1 cm) was soaked with the mixture (100  $\mu$ l), dried and placed at the bottom of a cuvette (inner diameter 1 cm) to prepare a substrate reagent.

This substrate reagent can be used as a kit for testing periodontal diseases according to the same manner as described in Example 4.

### Claims

25 1. A reagent for testing periodontal diseases which diagnoses or prognosticates contraction or progress of said diseases by determining aminopeptidase-like enzymatic activity in a specimen, said reagent comprises as a substrate for the enzyme either or both compounds of the formula:

X-Z-Arg-Y [1]

30 wherein Arg is arginine residue; X is hydrogen or an amino blocking group; Y is a color developing group attached to the C-terminal of Arg; and Z is an amino acid or peptide residue composed of 1 to 4 amino acids or their protected derivatives, the C-terminal of which is attached to the N-terminal of Arg, and

X'-Z'-Pro-Y' [2]

35 wherein Pro is proline residue; X' is hydrogen or an amino blocking group; Y' is a color developing group attached to the C-terminal of Pro; and Z' is an amino acid or peptide residue composed of 0 to 4 amino acids or their protected derivatives, the C-terminal of which is attached to the N-terminal of Pro.

2. A reagent according to claim 1, wherein X or X' is selected from formyl, acetyl, succinyl, t-butoxycarbonyl, benzoyl, carbobenzoxy and p-toluenesulfonyl.

3. A reagent according to claim 1, wherein Y of Y' is a member derived from a compound selected from  $\beta$ -naphthylamine, 4-methoxy-2-naphthylamine, p-nitroaniline, p-nitrophenol, 7-amino-4-methoxycoumarin, dimethyl-5-aminoisophthalate and 7-amino-4-trifluoromethylcoumarin.

4. A reagent according to claim 1, wherein the C-terminal amino acid residue in Z is a residue of glycine, lysine, arginine, phenylalanine or a blocked derivative thereof.

5. A reagent according to claim 1, wherein the C-terminal amino acid residue in Z' is a residue of glycine, lysine, phenylalanine or a blocked derivative thereof.

45 6. A reagent according to claim 1, wherein the substrate is a compound of the formula [1].

7. A reagent according to claim 1, wherein the substrate is a compound of the formula [2].

8. A reagent according to claim 1, wherein the substrate is both compounds of the formulas [1] and [2].

50 9. A method for diagnosing or prognosticating contraction or progress of periodontal diseases which comprises determining aminopeptidase-like enzymatic activity in a specimen by using as a substrate for the enzyme either or both compounds of the formula:

X-Z-Arg-Y [1]

wherein Arg is arginine residue; X is hydrogen or an amino blocking group; Y is a color developing group attached to the C-terminal of Arg and Z is an amino acid or peptide residue composed of 1 to 4 amino acids or their blocked derivatives, the C-terminal of which is attached to the N-terminal of Arg, and

55 X'-Z'-Pro-Y' [2]

wherein Pro is proline residue; X' is hydrogen or an amino blocking group; Y' is a color developing group attached to the C-terminal of Pro; and Z' is an amino or peptide residue composed of 0 to 4 amino acids or their blocked derivatives, the C-terminal of which is attached to the N-terminal of Pro.

10. A process for the production of a reagent according to any one of claims 1 to 8.

60 11. use of either or both of the compounds of formula [1] or formula [2] as defined in claim 1 in the preparation of a reagent for diagnosing or prognosticating contraction or progress of periodontal diseases.



L1 1 EP126685/PN

=> d 11 ibib abs


L1 ANSWER 1 OF 1 CA COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 102:204299 CA Full-text  
TITLE: Acylated water-soluble peptides or amino acids  
and  
their use  
INVENTOR(S): Monsigny, Michel; Mayer, Roger  
PATENT ASSIGNEE(S): Centre National de la Recherche Scientifique,  
Fr.  
SOURCE: Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 126685	A1	19841128	EP 1984-400984	19840515 <-

R: AT, BE, CH, DE, GB, IT, LI, LU, NL, SE  
FR 2546163 A1 19841123 FR 1983-8051 19830516  
FR 2546163 B1 19871009  
JP 60004158 A2 19850110 JP 1984-97419 19840515  
FR 1983-8051 19830516  
PRIORITY APPLN. INFO.:  
AB Title compds. R1(CHOH)mCO(NHCHRCO)nX [R = amino acid substituent,  
which may be different for n > 1 (n = 1-10); R1 = H, Me; m = 2-7;  
X = substituent which confers coloration, fluorescence, or  
pharmacol activity] were prepared for use as enzyme inhibitors and  
prodrugs. Thus, H-Ala-Ala-Pro-Ala-OH was N-acylated with glucono-  
δ-lactone and then amidated with 3-amino-9-ethylcarbazole (AEC) to  
give PHA-Ala-Ala-Pro-Ala- AEC. (PHA = polyhydroxyalkanoyl =  
R1(CHOH)mCO) (I). A solution of I and elastase was prepared and  
the intensity of the measured fluorescence was proportional to the  
quant. of enzyme in the solution

L2 ANSWER 1 OF 1 CA COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 128:295058 CA Full-text  
TITLE: Production and use of modified cytostatic  
agents  
INVENTOR(S): Lerchen, Hans-Georg; Von Dem Bruch, Karsten;  
Baumgarten, Jorg; Sperzel, Michael  
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany; Lerchen,  
Hans-Georg; Von Dem Bruch, Karsten;  
Baumgarten, Jorg;  
Sperzel, Michael  
SOURCE: PCT Int. Appl., 60 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9815571	A1	19980416	WO 1997-EP5189	19970922
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19640970	A1	19980416	DE 1996-19640970	19961004 <-
AU 9747766	A1	19980505	AU 1997-47766	19970922
EP 929570	A1	19990721	EP 1997-910326	19970922
R: DE, ES, FR, GB, IT				
JP 2001502308	T2	20010220	JP 1998-517120	19970922
PRIORITY APPLN. INFO.:			DE 1996-19640970 A	19961004
			WO 1997-EP5189 W	19970922
OTHER SOURCE(S):			MARPAT 128:295058	
GI				



I

AB The invention concerns conjugates of cytostatic agents and N-thiocarbonyl-modified amino acids and peptides, e.g. (I). The invention further concerns processes for their preparation and their use as medicaments, in particular in connection with cancers. Thus, I was synthesized from N-benzyloxy-carbonyl-D-alanine, batracylin, and N-(t-butoxy-carbonyl)-L-serine, in 98% yield. In in-vitro tests with colon cancers SW 480 and HT 29, I had IC50 of 25 and 40/μM, resp.